摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(β-D-ribofuranosyl)benzimidazole | 728-01-8

中文名称
——
中文别名
——
英文名称
1-(β-D-ribofuranosyl)benzimidazole
英文别名
1-β-D-Ribofuranosylbenzimidazol;1'-deoxy-1'-(benzimidazol-1-yl)-β-D-ribofuranose;benzimidazole riboside;1,3-dideazapurine riboside;(2R,3R,4S,5R)-2-(1H-1,3-benzodiazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol;(2R,3R,4S,5R)-2-(benzimidazol-1-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(β-D-ribofuranosyl)benzimidazole化学式
CAS
728-01-8
化学式
C12H14N2O4
mdl
——
分子量
250.254
InChiKey
VQJDOEMQZNKEMJ-DDHJBXDOSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    111-112 °C
  • 沸点:
    554.5±60.0 °C(Predicted)
  • 密度:
    1.62±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.2
  • 重原子数:
    18
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    87.7
  • 氢给体数:
    3
  • 氢受体数:
    5

SDS

SDS:1fbd3c09ec27cc382854c2dd35d52e15
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    1-(β-D-ribofuranosyl)benzimidazole4-二甲氨基吡啶偶氮二异丁腈四丁基氟化铵三正丁基氢锡 作用下, 以 四氢呋喃吡啶甲苯乙腈 为溶剂, 反应 4.25h, 生成 1-(2'-deoxy-β-D-ribofuranosyl)-1H-benzimidazole
    参考文献:
    名称:
    核苷和核苷酸。第25部分:受保护的1-(2'-脱氧-β-D-核呋喃糖基)-1 H-苯并咪唑3'-磷酸的合成†
    摘要:
    1-(2′-脱氧-5′ - O-二甲氧基三苯甲基-′- D-呋喃呋喃糖基)-1 H-苯并咪唑3′-[(对氯苯基)(2-氰基乙基)磷酸酯](6)的合成-(β-D-呋喃呋喃糖基)-1 H-苯并咪唑(3b)使用区域特异性2'-脱氧作用。后一种化合物是通过苯并咪唑与仅由β-D-端基异构体引起的D-核糖衍生物2的糖基化而获得的。
    DOI:
    10.1002/hlca.19870700117
  • 作为产物:
    参考文献:
    名称:
    Deprotection of α-imidazole/benzimidazole ribonucleosides by catalytic carbon tetrabromide initiated photolysis
    摘要:
    Several protected benzimidazole and imidazole alpha-ribonucleosides were deprotected in excellent yield Lit ambient temperature using CBr4 initiated photolysis in methanol at ambient temperature. No selectivity was observed and both trityl and isopropylidene groups were deprotected Under the reaction conditions. (c) 2005 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.tetlet.2005.09.180
点击查看最新优质反应信息

文献信息

  • Structure‐Guided Tuning of a Selectivity Switch towards Ribonucleosides in <i>Trypanosoma brucei</i> Purine Nucleoside 2′‐Deoxyribosyltransferase
    作者:Jon Del Arco、Alberto Mills、Federico Gago、Jesús Fernández‐Lucas
    DOI:10.1002/cbic.201900397
    日期:2019.12.13
    ribonucleosides are the best donors (inosine>guanosine≫adenosine), whereas no significant preferences exist between 6-aminopurines and 6-oxopurines as base acceptors. In contrast, no transferase activity could be detected on xanthine and 7-deazapurines. TbPDTY5F was successfully employed in the synthesis of a wide range of modified ribonucleosides containing different purine analogues.
    核苷2'-脱氧核糖基转移酶(NDTs)用作核苷类似物的工业合成的生物催化剂经常受到严格偏爱2'-脱氧核糖核苷的阻碍。本文显示,来自布鲁氏锥虫(TbPDT)的高度通用的嘌呤NDT也可以接受核糖核苷作为底物;这很可能是由于Asn53在其他NDT中通常被Asp占据的位置所起的独特作用。此外,按照结构指导的方法,通过在位置5引入单个氨基酸替代,将这种异常活性提高了约三倍。生物物理和生化特征表明,TbPDTY5F变体是同型二聚体,在50°C和pH 6.5下显示最大活性,并显示69°C的极高熔化温度。底物特异性研究表明6-氧嘌呤核糖核苷是最好的供体(肌苷>鸟苷≫腺苷),而6-氨基嘌呤和6-氧嘌呤作为碱基受体没有明显的偏爱。相反,在黄嘌呤和7-脱氮嘌呤上未检测到转移酶活性。TbPDTY5F已成功用于合成包含不同嘌呤类似物的多种修饰的核糖核苷。
  • Synthesis of the 3′,5′-Cyclic Phosphates from Unprotected Nucleosides
    作者:H. -G. Genieser、E. Butt、U. Bottin、W. Dostmann、B. Jastorff
    DOI:10.1055/s-1989-27150
    日期:——
    Unprotected nucleosides were phosphorylated with phosphoryl chloride in trialkyl phosphates and subsequently cyclized with base to give 3′,5′-cyclic nucleotides in good yields.
    未保护的核苷在三烷基磷酸酯中用磷酰氯进行磷酸化,随后用碱进行环化,良好产率地得到3′,5′-环状核苷酸。
  • Synthesis of benzimidazole nucleosides and their anticancer activity
    作者:Vaishali S. Shinde、Pravin P. Lawande、Vyankat A. Sontakke、Ayesha Khan
    DOI:10.1016/j.carres.2020.108178
    日期:2020.12
    An efficient route for the synthesis of benzimidazole nucleosides 1-8 from readily available d-glucose via 3,5-dihydroxy-1,2-O-isopropylidene-α-d-ribofuranose and 3-azido-3-deoxy-1,2-O-isopropylidene-α-d-xylofuranose intermediates has been adopted. Ribofuranosyl nucleosides 1-4 with different benzimidazole bases, and 3'-deoxy-3'-azido-ribofuranosyl nucleosides 5-8, as another series, were obtained
    通过 3,5-dihydroxy-1,2-O-isopropylidene-α-d-ribofuranose 和 3-azido-3-deoxy-1,2 从容易获得的 d-葡萄糖合成苯并咪唑核苷 1-8 的有效途径-O-异亚丙基-α-d-呋喃木糖中间体已被采用。获得了具有不同苯并咪唑碱基的呋喃核糖核苷1-4和作为另一系列的3'-脱氧-3'-叠氮基-呋喃核苷核苷5-8。使用 MDA-MB-231 细胞系评估所有这些新合成的类似物的抗癌活性。在不同取代的衍生物中,3'-叠氮化物取代的核苷 (5-8) 比呋喃核糖基类似物 1-4 更有效。在核碱基的 2 位具有蒽基的 C-3'-叠氮基类似物 8 显示出与标准依托泊苷几乎相似的效力。
  • C−F···H−C Hydrogen Bonds in Ribonucleic Acids
    作者:Jörg Parsch、Joachim W. Engels
    DOI:10.1021/ja012116g
    日期:2002.5.1
    contributions for base stacking and solvation of all modified building blocks. Comparison of calculated and measured data of double modified base pairs in 12mer RNA duplexes showed a further duplex stabilizing force in base pairs containing fluorine atoms at the Watson-Crick binding site. This stabilizing force can be defined as C-F.H-C hydrogen bond as is observed in crystal structures of 1'-deoxy-1'
    我们报告了 1'-deoxy-1'-(benzimidazol-1-yl)-beta-D-ribofuranose 7 和 1'-deoxy-1'-phenyl-beta-D-ribofuranose 2 的合成。 使用这两种核糖核苷类似物我们手头有一组九种不同的 RNA 构建块,它们与天然碱基是等排的。现在可以研究它们的双重稳定力。这些力是氢键、碱基堆积和溶剂化。所有构建块的亚磷酰胺都被整合到 12 聚体 RNA 中,并通过 UV 和 CD 光谱研究了所得的 RNA 双链体。我们发现一些 RNA 类似物是通用碱基。具有最低不稳定和最小天然碱基区分度的最佳通用碱基是 1 (B) 和 9 (E)。在紫外线测量的基础上,我们确定了熔点和热力学数据。我们能够证明天然碱基和 RNA 类似物之间没有氢键。根据热力学数据,我们计算了所有改性构件的基础堆积和溶剂化的贡献。12mer RNA 双链体中双修饰碱基对的计算和测量数据的比较表明,在
  • [EN] METHOD OF USING (H/K) ATPase INHIBITORS AS ANTIVIRAL AGENTS<br/>[FR] PROCEDE D'UTILISATION D'INHIBITEURS DE (H/K)ATPASE COMME AGENTS ANTIVIRAUX
    申请人:G.D. SEARLE & CO.
    公开号:WO1995029897A1
    公开(公告)日:1995-11-09
    (EN) A class of compounds which are (H+/K+) ATPase inhibitors can be used for the treatment of viral infections. Compounds of particular interest are defined by formula (III), wherein D is N or CH; wherein R7 is one or more radicals selected from hydrido, alkoxy, amino, cyano, nitro, hydroxyl, alkyl, halo, haloalkyl, carboxyl, alkanoyl, nitro, amino, alkylamino, aminocarbonyl, aminosulfonyl, alkylaminocarbonyl, alkylcarbonylamino, alkoxycarbonyl, alkylaminosulfonyl, alkylsulfonylamino, alkylthio, alkylsulfinyl and alkylsulfonyl; wherein R8 is selected from hydrido, alkyl and cycloalkyl; wherein R9 is one or more radicals selected from hydrido, alkoxy, amino, alkyl, halo, cyano, nitro, hydroxyl, haloalkyl, nitro, carboxyl, alkanoyl, amino, alkylamino, dialkylamino, aminocarbonyl, alkylaminocarbonyl, alkylcarbonylamino, aminosulfonyl, alkylaminosulfonyl, alkylsulfonylamino, alkoxycarbonyl, alkylthio, alkylsulfinyl and alkylsulfonyl; and wherein R10 and R11 are independently selected from hydrido, alkyl, aryl, alkylcarbonyl and arylcarbonyl wherein the aryl ring may be further substituted with one or more radicals selected from alkyl, halo, hydrazidylcarbonyl, aminocarbonyl and alkoxy; or wherein R10 and R11 together with the nitrogen atom form a heterocyclic ring; or a pharmaceutically acceptable salt thereof.(FR) Une classe de composés qui sont des inhibiteurs de (H+/K+)ATPase peut être utilisée pour le traitement d'infections virales. Les composés particuliers à examiner sont définis par la formule (III), dans laquelle D représente N ou CH; R7 représente un ou plusieurs radicaux choisis entre hydrido, alcoxy, amino, cyano, nitro, hydroxyle, alkyle, halo, haloalkyle, carboxyle, alcanoyle, nitro, amino, alkylamino, aminocarbonyle, aminosulfonyle, alkylaminocarbonyle, alkylcarbonylamino, alcoxycarbonyle, alkylaminosulfonyle, alkylsulfonylamino, alkylthio, alkylsulfinyle et alkylsulfonyle; R8 est choisi entre hydrido, alkyle et cycloalkyle; R9 représente un ou plusieurs radicaux choisis entre hydrido, alcoxy, amino, alkyle, halo, cyano, nitro, hydroxyle, haloalkyle, nitro, carboxyle, alcanoyle, amino, alkylamino, dialkylamino, aminocarbonyle, alkylaminocarbonyle, alkylcarbonylamino, aminosulfonyle, alkylaminosulfonyle, alkylsulfonylamino, alcoxycarbonyle, alkylthio, alkylsulfinyle, et alkylsulfonyle; et R10 et R11 sont indépendamment choisis entre hydrido, alkyle, aryle, alkylcarbonyle, et arylcarbonyle, le noyau aryle pouvant être en outre substitué par un ou plusieurs radicaux choisis entre alkyle, halo, hydrazidylcarbonyle, aminocarbonyle et alcoxy; ou R10 et R11 forment avec l'atome d'azote un noyau hétérocyclique; ou leur sel pharmaceutiquement acceptable.
    一类(H+/K+) ATPase抑制剂化合物可用于治疗病毒感染。特别感兴趣的化合物由公式(III)定义,其中D是N或CH;R7是一个或多个从氢基,烷氧基,氨基,氰基,硝基,羟基,烷基,卤基,卤基烷基,羧基,烷酰基,硝基,氨基,烷基氨基,氨基甲酰基,氨基磺酰基,烷基氨基甲酰基,烷基羰基氨基,烷氧羰基,烷基氨基磺酰基,烷基磺酰胺基,烷硫基,烷基亚磺酰基和烷基磺酰基中选择的基团;R8选择从氢基,烷基和环烷基中选择;R9是一个或多个从氢基,烷氧基,氨基,烷基,卤基,氰基,硝基,羟基,卤基烷基,硝基,羧基,烷酰基,氨基,烷基氨基,二烷基氨基,氨基甲酰基,烷基氨基甲酰基,烷氧羰基,烷基氨基磺酰基,烷基磺酰胺基,烷基亚磺酰基,烷氧羰基,烷硫基,烷基亚磺酰基和烷基磺酰基中选择的基团;R10和R11分别选择从氢基,烷基,芳基,烷基羰基和芳基羰基中选择,其中芳环可以进一步取代一个或多个从烷基,卤基,肼基羰基,氨基羰基和烷氧基中选择的基团;或者R10和R11与氮原子一起形成杂环环;或其药学上可接受的盐。
查看更多

同类化合物

[(2R,3R,4R,5R)-2-(5,6-二氯苯并咪唑-1-基)-4-羟基-5-(羟基甲基)四氢呋喃-3-基]磷酸二氢酯 BENZIMIDAVIR苯并咪唑核苷 5,6-二甲基-1-(5-O-膦酰-alpha-D-呋喃核糖基)-1H-苯并咪唑 5,6-二氯-1-β-D-呋喃核糖基苯并咪唑 2-氯-5,6-二甲基-1-beta-D-呋喃核糖基苯并咪唑 2,5-哌嗪二酮,3-甲基-6-(2-甲基丙基)-,反-(9CI) 1,3-二去氮杂腺苷 (2S,3R,4S,5R)-2-(5,6-二甲基苯并咪唑-1-基)-5-(羟基甲基)四氢呋喃-3,4-二醇 5,6-dichloro-2-<(4-chlorobenzyl)thio>-1-β-D-ribofuranosylbenzimidazole 5,6-dichloro-2-<(4-nitrobenzyl)thio>-1-β-D-ribofuranosylbenzimidazole 9-(1-β-D-arabinofuranosyl)-6-nitro-1,3-dideazapurine 9-(1-β-D-arabinofuranosyl)-1,3-dideazaadenine 1-(2,3-O-isopropylidene-β-D-ribofuranosyl)benzimidazole 1-(2,3-O-isopropylidene-α-D-ribofuranosyl)benzimidazole 2-{3-[3-(4-carbamoylpiperidin-1-yl)propoxy]benzylamino}-1-(β-D-ribofuranosyl)-1H-benzimidazole 5-chloro-1-(5-O-sulfamoyl-β-D-ribofuranosyl)-1H-benzimidazole 2-bromo-5,6-dichloro-5'-O-L-lysyl-1-β-D-ribofuranosylbenzimidazole 2-(sec-Butylamino)-5,6-dichloro-1-(beta-L-ribofuranosyl)-1H-benzimidazole 2,5-dimethyl-1-(β-D-erythropentofuranosyl)-1H-benzimidazole 1-β-D-arabinofuranosylbenzimidazole 5,6-Dichloro-1-(beta-L-ribofuranosyl)-2-((2,2,2-trifluoroethyl)amino)-1H-benzimidazole 2-(3-bromobenzylamino)-1-(β-D-ribofuranosyl)-1H-benzimidazole 5,6-dichlorobenzimidazole riboside-5'-O-triphosphate 1,3-bis(β-D-ribofuranosyl)-2-thio-5,6-dichlorobenzimidazole 5,6-dichloro-2-<<3-(trifluoromethyl)benzyl>thio>-1-β-D-ribofuranosylbenzimidazole 2-chloro-5,6-dinitro-1-(β-D-ribofuranosyl)benzimidazole 2-Morpholino-1-(β-D-ribofuranosyl)-benzimidazol 1H-Benzimidazole, 1-(5-O-(hydroxy(phosphonooxy)phosphinyl)-beta-D-ribofuranosyl)- 1H-Benzimidazole, 1-ribofuranosyl- lin.-Benzo-ATP (2R,3R,4S,5S)-2-(5,6-dichloro-2-sulfanyl-benzimidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol α-ribazole-3'-phosphate 5,6-Dichloro-2-(methylamino)-1-(beta-L-ribofuranosyl)-1H-benzimidazole 1-(2',3',5'-tri-O-benzoyl-β-D-ribofuranosyl)-1H-benzimidazole (2R,3R,4S,5R)-2-(5,6-dichloro-2-methyl-benzimidazol-1-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol (2S,3S,4R,5R)-2-(5,6-Dichloro-2-mercapto-benzoimidazol-1-yl)-5-hydroxymethyl-tetrahydro-furan-3,4-diol 1-<5'-O-(tert-butyldimethylsilyl)-β-D-ribofuranosyl>-5,6-dichloro-2-mercaptobenzimidazole Benzimidazole, 2-chloro-1-beta-D-ribofuranosyl- 2-(Morpholin-4-yl)-1-pentofuranosyl-1h-benzimidazole 1-Pentofuranosyl-2-(piperidin-1-yl)-1h-benzimidazole 2-Methoxy-1-pentofuranosyl-1h-benzimidazole 2-(Methylsulfanyl)-1-pentofuranosyl-1h-benzimidazole 2-(Benzylsulfanyl)-1-pentofuranosyl-1h-benzimidazole N-Methyl-1-pentofuranosyl-1,3-dihydro-2H-benzimidazol-2-imine 1-Pentofuranosyl-1,3-dihydro-2H-benzimidazol-2-imine 1-Pentofuranosyl-1H-benzimidazol-2-ol n,n-Dimethyl-1-pentofuranosyl-1h-benzimidazol-2-amine 5,6-Dimethyl-1-pentofuranosyl-1,3-dihydro-2H-benzimidazol-2-imine 2-(Benzylsulfanyl)-5,6-dimethyl-1-pentofuranosyl-1h-benzimidazole 5,6-Dimethyl-2-(methylsulfanyl)-1-pentofuranosyl-1h-benzimidazole